Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).

被引：0
|
作者：
Hillmen, P.
Skotnicki, A.
Robak, T.
Jaksic, B.
机构：
[1] Gen Infirm, Leeds Teaching Hosp NHS Trust, Leeds LS1 3EX, W Yorkshire, England
[2] Jagiellonian Univ, Coll Med, Krakow, Poland
[3] Kopernik Mem Hosp, Lodz, Poland
[4] Clin Hosp, Zagreb, Croatia
[5] Med Univ Lublin, Lublin, Poland
[6] Genzyme, Boston, MA USA
[7] Univ Hosp, Brno, Czech Republic
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：339S / 339S
页数：1
相关论文
共 50 条
  • [1] Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Robak, T
    Skotnicki, AB
    Mayer, J
    Vukovic, V
    Weitman, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 573S - 573S
  • [2] Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Dmoszynska, A.
    Fetni, R.
    Wang, Y.
    Belkaci, M.
    Sirard, C.
    Goldberg, M.
    Mayer, J.
    Robak, T.
    Skotnicki, A.
    Hillmen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 361S - 361S
  • [3] Preliminary safety and efficacy report of a randomized trial of alemtuzumab vs chlorambucil as front-line therapy in 297 patients with progressive B-cell chronic lymphocytic leukemia.
    Hillmen, P
    Skotnicki, AB
    Robak, T
    Mayer, J
    Jaksic, B
    Vukovic, V
    Weitman, S
    BLOOD, 2004, 104 (11) : 687A - 687A
  • [4] Alemtuzumab (CAMPATH®,MABCAMPATH®) has superior progression free survival (PFS) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Hillmen, Peter
    Skotnicki, Aleksander
    Robak, Tadeusz
    Jaksic, Branimir
    Sirard, Cynthia
    Mayer, Jiri
    BLOOD, 2006, 108 (11) : 93A - 93A
  • [5] Phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (CAMPATH®, MABCAMPATH®) vs. chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia (CAM307).
    Skotnicki, AB
    Robak, T
    Mayer, J
    Craig, A
    Weitman, S
    BLOOD, 2003, 102 (11) : 439A - 439A
  • [6] Progression free survival is superior with alemtuzumab vs chlorambucil as front-line therapy for patients with B-cell chronic lymphocytic leukemia
    Hillmen, P.
    Skotnicki, A.
    Robak, T.
    Jaksic, B.
    Sirard, C.
    Mayer, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 45 - 46
  • [7] Incidence of genomic aberrations and associated efficacy from a phase III study comparing alemtuzumab (CAMPATH®, MABCAMPATH®) vs chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia (BCLL).
    Robak, Tadeusz
    Dmoszynska, Anna
    Fetni, Raouf
    Wang, Ying
    Belkacz, Malika
    Sirard, Cynthia
    Goldberg, Mark
    Skotnicki, Aleksander
    Mayer, Jiri
    Hillmen, Peter
    BLOOD, 2006, 108 (11) : 593A - 593A
  • [8] Impact of prognostic factors on outcome in a phase III study comparing alemtuzumab to chlorambucil as first-line therapy for B-cell chronic lymphocytic leukemia (BCLL)
    Mayer, J.
    Robak, T.
    Skotnicki, A.
    Jaksic, B.
    Dmoszynska, A.
    Sirard, C.
    Hillmen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B-cell chronic lymphatic leukemia
    Mabed, M
    Aref, S
    Fouda, M
    El-Sharawy, S
    LEUKEMIA & LYMPHOMA, 2004, 45 (10) : 2029 - 2035
  • [10] EFFICACY AND SAFETY OF CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY AND/OR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. A GIMEMA RETROSPECTIVE STUDY
    Laurenti, L.
    Autore, F.
    Innocenti, I.
    Vannata, B.
    Ciolli, S.
    Mauro, F. R.
    Mannina, D.
    Del Poeta, G.
    D'Arena, G.
    Massaia, M.
    Coscia, M.
    Molica, S.
    Pozzato, G.
    Marasca, R.
    Galieni, P.
    Cuneo, A.
    Orlando, S.
    Piciocchi, A.
    Boncompagni, R.
    Vincelli, D.
    Liberati, A. M.
    Russo, F.
    Foa, R.
    HAEMATOLOGICA, 2015, 100 : 134 - 134
12345